Back to Trials
NCT07006428NARecruiting

Visual Performance of Clareon PanOptix vs. a Comparable Multifocal Intraocular Lens

Argus Research Center, Inc.

Start Date

5/7/2025

Completion Date

11/1/2025

Summary

This is a two-part, multi-center, investigator-initiated clinical study comparing visual outcomes and patient satisfaction in subjects receiving bilateral implantation of either the Clareon PanOptix intraocular lens (IOL) or a comparable multifocal IOL. The study includes a retrospective/prospective pilot phase and a prospective, randomized comparison phase.

Eligibility Criteria

Age Range: No minimum to No maximum

Inclusion Criteria: Stage 1: IIT Pilot * Willing and able to understand and sign informed consent. * Adult patients previously diagnosed with age-related cataracts bilaterally. * Previous bilateral age-related cataract removal and with bilateral implantation of the Clareon PanOptix/ Clareon PanOptix Toric (T3-T4) or Comparable Multifocal Intraocular Lens (equivalent to T3-T4) closest to 2.5-5-months after implantation and \>2 weeks post YAG (if done) that were targeted for emmetropia. * Best monocular corrected distance visual acuity was expected to be 0.1 logMAR (Snellen 20/25) or better in both eyes pre-operatively as determined by surgeon. * Normal ocular findings aside from cataract. Stage 2: Comparison * Willing and able to understand and sign informed consent. * Adult patient diagnosed with age-related cataracts bilaterally. * Planned bilateral cataract removal by femtosecond laser-assisted phacoemulsification with bilateral implantation of the Clareon PanOptix/Clareon PanOptix Toric (T3-T4) or Comparable Multifocal Intraocular Lens (equivalent to T3-T4). * Best monocular corrected distance visual acuity expected to be 0.1 logMAR (Snellen 20/25) or better in both eyes postoperatively as determined by surgeon. * Residual astigmatism expected to be ≤ 0.50 diopters in both eyes postoperatively as determined by surgeon (after using either toric IOL or arcuate incision with laser). * Normal ocular findings aside from cataract. Exclusion Criteria: Stage 1: IIT Pilot * Corneal pathology, irregular astigmatism, preexisting macular disease and other retinal degenerative diseases, diabetic retinopathy that is expected to cause future vision loss, glaucoma, severe dry eye disease, nystagmus, strabismus, zonular laxity or dehiscence, pseudoexfoliation. * Previous history of any ocular surgery including corneal refractive surgery. * Participation in another clinical study that could interfere with the results. * Patients with monovision correction. * Any active ocular infection or inflammation. Stage 2: Comparison * Corneal pathology, irregular astigmatism, preexisting macular disease and other retinal degenerative * diseases that is expected to cause future vision loss, glaucoma, severe dry eye disease, nystagmus, strabismus, zonular laxity or dehiscence, pseudoexfoliation. * Previous history of any ocular surgery including corneal refractive surgery. * Participants desiring monovision. * History of amblyopia or monofixation syndrome with poor stereoscopic vision. * Total corneal HOA greater than 0.6um, coma less than 0.3um at 4mm-5mm scan depending on pre- op photopic topography. * Any planned simultaneous/combined procedures at time of cataract surgery (e.g. MIGs). * Participation in another clinical study that could interfere with the results. * Any active ocular infection or inflammation.

Interventions

DEVICE

Clareon PanOptix or PanOptix Toric IOLs

DEVICE

Comparable multifocal IOL

Interested in This Trial?

Contact the trial locations directly using the information below to learn more about enrollment.

Expressing interest lets you review the study and consent before we connect you with the research site.

Conditions

Age Related Cataracts

Locations

Wolstan & Goldberg Eye Associates

Torrance, California 90505

United States

Tyson Eye

Cape Coral, Florida 33904

United States

North Georgia Eye Associates

Gainesville, Georgia 30501

United States